CUREVAC N.V. overview

Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended into Q4 2025 with organizational redesign and despite PPA wind-down Strategic collaboration signed...

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone Avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /...

Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"),...

Issuer: CureVac / Key word(s): Annual Results CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update 24.04.2024 / 13:06 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs...

Issuer: CureVac / Key word(s): Study CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK 24.04.2024 / 13:03 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza...

Issuer: CureVac / Key word(s): Personnel CureVac Appoints Thaminda Ramanayake as New Chief Business Officer 24.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST. Dial-in numbers to participate in...

Issuer: CureVac / Key word(s): Miscellaneous CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 18.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 TÜBINGEN, Germany/BOSTON, USA – April 18, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company...